Wilate

Wilate is a human-derived coagulation factor concentrate combining Factor VIII and von Willebrand Factor for intravenous use. This dual-factor therapy supports hemostasis in bleeding disorders. Suitable for patients with hemophilia A or von Willebrand disease. EU-sourced and manufactured by Octapharma.

Wilate is used to prevent and control bleeding episodes in patients with hemophilia A, a genetic disorder causing impaired blood clotting. It is also indicated for von Willebrand disease, a condition where blood lacks sufficient von Willebrand factor, leading to prolonged bleeding. This medication helps replace missing or defective clotting proteins. what is wilate used for

After administration, Wilate works by increasing levels of Factor VIII and von Willebrand Factor in the bloodstream. This supports the natural clotting process, reducing bleeding risk in affected individuals. Effects vary based on individual response and condition severity. No immediate relief should be expected without proper medical guidance.

Wilate should be handled with care to avoid contamination or improper administration. It is intended for intravenous use only and must be prepared according to sterile procedures. Patients should inform healthcare providers of any allergies or prior reactions to blood products. Storage conditions should be strictly followed to maintain potency.

Wilate may interact with other medications affecting blood clotting, such as anticoagulants or antiplatelet drugs. Combining it with these could alter bleeding risk. No known interactions with common non-prescription products like vitamins or herbal supplements have been established. Always disclose all medications to a healthcare professional before use.